How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Infectious Disease Archives

FDA Decisions to Watch Q1-Q2: Infectious Disease

State of Kansas Reports Country’s Largest Tuberculosis Outbreak

Immune Deficits in Some Valley Fever Patients Hinder Response to Antifungal Treatment

Copay Assistance is Not Going Towards Patient Deductibles Thus Leaving People With Out-of-Pocket Costs

Improving Antibiotic Stewardship for UTIs in Ambulatory Settings

In Response to Outbreak, 2-Dose Hepatitis E Vaccines Shows High Efficacy

Fungal Infection Diagnosis, Misdiagnoses, and Global Health Initiatives

Novel Compound Demonstrates Activity Against Vancomycin-Resistant Enterococci

The Top 5 Infectious Disease News Stories Week of January 18-25

Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile

Schedule an Appointment

Quick Links

Patient Forms

Contact Us